Federal & State Policy
As the largest, single US healthcare payer, the government plays a dominant role in shaping the healthcare marketplace. Our experts track, interpret, and model federal and state policies that affect insurance coverage, access, and consumer choice so you can see around the bend.
New research from Avalere finds that Medicare Advantage (MA) beneficiaries with hypertension, hyperlipidemia, and diabetes experienced significantly fewer inpatient stays and emergency room visits relative to those in traditional fee-for-service (FFS) Medicare.
On June 27, CMS notified Massachusetts of a partial approval of the MassHealth program’s proposed 1115 waiver request.
On June 19, the Department of Labor (DOL) released its final rule on Association Health Plans (AHP).
2019 rate filings suggest increased competition and plan choice
Maine had the greatest decline at 25% compared with the national average of 11%.
In its 2018 Report, the Medicare Trustees issued a Medicare funding warning, citing concerns over the program's near-term financial health and spending impact on the federal budget.
Avalere analysis finds that price of generic drugs has remained flat but the cost to seniors is increasing.
Patient out-of-pocket costs continue to grow despite policies to increase affordability for beneficiaries.
Avalere's founder and president, Dan Mendelson, recently sat down with Senior Housing News editors to discuss opportunities for senior living providers to leverage data to facilitate synergistic partnerships with payers.
Avalere evaluated payer policies for biologics when biosimilars are available.
The House and Senate are advancing legislative packages aimed at mitigating the crisis.
Avalere examines the effect of foundation-sponsored financial assistance on out-of-pocket costs and federal spending.
Coordinated information sharing can facilitate the delivery of integrated care to patients using both physical and behavioral health services.
In response to the concern that overprescribing is a driver of the opioid crisis, payers are limiting opioid fills as one solution.
The Centers for Medicare & Medicaid Services released the final Notice of Benefit and Payment Parameters (NBPP) for the 2019 plan year.
In just two years, on March 23, 2020, biologics currently regulated as drugs will transition to being regulated as biologics. Many aspects of how FDA will implement this transition have yet to be established.
On March 6, Avalere experts came together to discuss the latest Medicaid developments.
New research from Avalere finds Medicare beneficiaries are spending fewer days in skilled nursing facilities (SNFs) since 2009 on a per capita basis.
Avalere experts discuss an evolving Medicaid program supported by a new administration and novel state approaches.
New analysis from Avalere finds that the proposed rule on association health plans (AHPs) is projected to lead to 3.2M enrollees shifting out of the Affordable Care Act's (ACA) individual and small group markets into AHPs by 2022.